The Idea: For nearly 30 years, Tim Spector ran the world's largest twin registry at King's College London. Then he found something that broke his own field: identical twins, same exact genes, could have wildly different responses to the same meal. The difference came down to two things nobody was studying at scale — the food people ate, and the microbes in their gut. Spector wanted to prove it. He recruited Jonathan Wolf, who'd just scaled ad-tech firm Criteo to a $1B NASDAQ IPO, and George Hadjigeorgiou, a serial consumer-app founder. Spector's condition: no product until they had real data. So Wolf set out to fund a three-year nutrition study with no product, no revenue, and no guarantee it would work. This was the beginning of ZOE.
The Execution
- 2017: Spector, Wolf, and Hadjigeorgiou founded ZOE ("life" in Greek) and launched PREDICT, the largest in-depth nutrition study in the world, run with scientists from King's College London, Stanford, Harvard's T.H. Chan School and Massachusetts General. Three years of science before a single dollar of product revenue.
- End of March 2020: Days before launching their first product, COVID hit. ZOE rebuilt its tech in roughly five days and launched the ZOE COVID Study app, which grew into the world's largest community science project on the virus with over 4 million contributors and helped identify loss of smell as a key symptom. Spector was awarded an OBE for the work.
- May 2021: ZOE closed its Series B at $53M total, topped up by a $20M round led by Ahren Innovation Capital, which counts two Nobel laureates among its backers, capital to finally launch the paid nutrition program.
- 2022: ZOE raised over $8.5M from its own members via crowdfunding, turning its community into shareholders, an unusually on-brand move for a "community science" company.
- December 2022: A £25M ($73M total) Series B extension led by Accomplice valued the company at £209M. Headcount had grown from five to 200+.
- May 2024: ZOE published a randomised controlled trial in Nature Medicine - the same gold-standard method used for drugs and vaccines. The committed-to-publish-regardless design meant a bad result could have ended the company. It didn't: ZOE members beat the control group on blood fat, weight, waist size and blood sugar. It launched in the US the same month.
- August 2024: Coefficient Capital invested $15M to fund US expansion, joining backers including Balderton, Daphni, and Steven Bartlett's Flight Fund. Membership had passed 100,000.
- Early 2025: Facing a brutal market, ZOE cut its UK membership 60% to £9.99/month, dropped the physical glucose monitors and blood-fat tests in favour of AI-predicted metrics, and cut headcount.
- October 2025: ZOE went back to its community on Crowdcube, with a stated goal of sequencing the gut profiles of one million people to train its "GutEngine" AI model - the data flywheel the whole company was built on, coming full circle.
The lesson? Most founders run from the experiment that could prove them wrong. Spector and Wolf built the entire company around it - three years of study before a single product was launched. They bet the company on being right. And when the pandemic torched their launch plan, the same instinct turned a five-day pivot into the most trusted brand in gut health. The product was always downstream of the proof.